Molecular differences between species of the
View Patent ↗Specific genetic deletion are identified in mycobacteria isolates, including variations in the M. tuberculosis genome sequence between isolates, and numerous deletion present in BCG as compared to M. tb. These deletions are used as markers to distinguish between pathogenic and avirulent strains, and as a marker for particular M. tb isolates. Deletions specific to vaccine strains of BCG are useful in determining whether a positive tuberculin skin test is indicative of actual tuberculosis infection. The deleted sequences may be re-introduced into BCG to improve the efficacy of vaccination. Alternatively, the genetic sequence that corresponds to the deletion(s) are deleted from M. bovis or M. tuberculosis to attenuate the pathogenic bacteria.
1. An immunogenic composition, comprising:
a substantially pure polypeptide encoded by a nucleotide sequence comprising the open reading frame Rv2660 (SEQ ID NO:100) or a polypeptide encoded by a nucleotide fragment of at least 25 contiguous nucleotides of SEQ ID NO:100 or where said polypeptide is fused to another peptide or protein; and a pharmaceutically acceptable excipient.
2. The immunogenic composition according to claim 1 , further comprising an adjuvant.
3. The immunogenic composition according to claim 1 , wherein said polypeptide is fused to another peptide or protein.
4. The immunogenic composition according to claim 1 , comprising a mycobacterium of the M. tuberculosis complex that has been modified by introduction of said nucleotide sequence comprising the open reading frame Rv2660 (SEQ ID NO:100) or nucleotide fragment of at least 25 contiguous nucleotides of SEQ ID NO:100.
5. The immunogenic composition according to claim 1 , wherein said polypeptide is co-formulated with a mycobacterium of the M. tuberculosis complex.
6. The immunogenic composition according to claim 4 , wherein said mycobacterium of the M. tuberculosis complex is bacillus Calmette-Guerin.
7. The immunogenic composition according to claim 4 , wherein said mycobacterium of the M. tuberculosis complex is M. bovis.
8. The immunogenic composition of claim 5 , wherein said mycobacterium of the M. tuberculosis complex is bacillus Calmette-Guerin.
9. The immunogenic composition according to claim 5 , wherein said mycobacterium of the M. tuberculosis complex is M. bovis.
10. A method of immunizing an individual to M. tuberculosis , the method comprising:
injecting said individual with a mycobacterium of the M. tuberculosis complex that has been modified to introduce a nucleotide sequence comprising the open reading frame Rv2660(SEQ ID NO:100) or nucleotide fragment of at least 25 contiguous nucleotides of SEQ ID NO:100, wherein said mycobacterium of the M. tuberculosis complex is bacillus Calmette-Guerin.
11. A method of immunizing an individual to M. tuberculosis , the method comprising:
injecting said individual with a polypeptide encoded by a nucleotide sequence comprising the open reading frame Rv2660 (SEQ ID NO:100) or a polypeptide encoded by a nucleotide fragment of at least 25 contiguous nucleotides of SEQ ID NO:100 or where said polypeptide is fused to another peptide or protein, wherein said polypeptide is co-formulated with bacillus Calmette-Guerin.
12. A genetically altered mycbacterium of the M. tuberculosis complex, comprising an exogenous nucleic acid sequence comprising the open reading frame Rv2660 (SEQ ID NO:100) or at least 25 contiguous nucleotides of SEQ ID NO:100.
13. The genetically altered mycbacterium of claim 12 , wherein said exogenous nucleic acid encodes a polypeptide that is fused to another peptide or protein.
14. The genetically altered mycbacterium of claim 12 , wherein said mycobacterium is BCG.
15. The mycbacterium of claim 12 , and a physiologically acceptable carrier for injection.